TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21614910

Group type: EXPERIMENTAL
Intervention: Collagen type I (Cellerate RX powder) applied in the axillary cavity after lymphadenectomy (n = 42)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard lymphadenectomy without sealant (Control group, n = 38)
Number of subjects: 80
Study: 20140352

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine during pregnancy (Group 1)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine after pregnancy (Group 2)
Number of subjects: 139

Group type: COMPARATOR
Intervention: No vaccine (Group 3)
Number of subjects: 139
Study: 17278336

Group type: EXPERIMENTAL
Intervention: Tempa.DOT (TDT) chemical dot thermometer
Number of subjects: 62

Group type: COMPARATOR
Intervention: Electronic thermometer (ETT)
Number of subjects: 62
Study: 15242424

Group type: EXPERIMENTAL
Intervention: AVP (4 U h(‐1)) and NE
Number of subjects: 38

Group type: COMPARATOR
Intervention: NE alone
Number of subjects: 38
Study: 11317948

Group type: EXPERIMENTAL
Intervention: Thought suppression (not thinking about the target thought)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control condition (thinking about anything)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: State and trait anxiety influence
Number of subjects: 112
Study: 9604230

Group type: EXPERIMENTAL
Intervention: Weight-adjusted LT4-dose in combination with 150 micrograms iodide (group A)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fixed combination of 100 micrograms LT4 plus 100 micrograms iodide (group B)
Number of subjects: 105
Study: 1655350

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 150 mg/die i.v. for 10 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1,000 mg/die i.v. for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo i.v. for 10 days (first study)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo i.v. for 10 days (second study)
Number of subjects: 20
Study: 6349949

Group type: EXPERIMENTAL
Intervention: Rigid sigmoidoscopy
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy
Number of subjects: 1007
Study: 31529492

Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin (BV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapies (physician's choice with either methotrexate or bexarotene)
Number of subjects: 0
Study: 27955919

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (2.0 mg/kg) administered weekly or every other week for 120 weeks
Number of subjects: 0
Study: 26694733

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 3455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: CE/BZA groups
Number of subjects: 3455

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 3455

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 3455
Study: 23716986

Group type: EXPERIMENTAL
Intervention: 0.4% sodium hyaluronate (SH)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 76
Study: 21309194

Group type: EXPERIMENTAL
Intervention: Fasting glucose 90 mg/dL or greater
Number of subjects: 1841

Group type: EXPERIMENTAL
Intervention: 1 hour glucose 165 mg/dL or greater
Number of subjects: 1841

Group type: EXPERIMENTAL
Intervention: 1 hour glucose 150 mg/dL or greater
Number of subjects: 1841

Group type: EXPERIMENTAL
Intervention: Fasting and all postload levels
Number of subjects: 1841
Study: 19132285

Group type: COMPARATOR
Intervention: Tolterodine extended release (TOL ER) for 24 weeks
Number of subjects: 161
Study: 17610195

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 3604

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3604
Study: 15268892

Group type: EXPERIMENTAL
Intervention: Risedronate (30 mg daily for 10 doses during the first 2 weeks, then once a week for 12 weeks)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 11296884

Group type: EXPERIMENTAL
Intervention: Single low-dose administration of 60 mg dihydrocodeine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chronic high-dosage administration of dihydrocodeine
Number of subjects: 26
Study: 10833290

Group type: EXPERIMENTAL
Intervention: Tenderfoot
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lancetta
Number of subjects: 40
Study: 8037259

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg p.o.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2906910

Group type: EXPERIMENTAL
Intervention: SAAVE
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 4309863

Group type: EXPERIMENTAL
Intervention: Topical oral corticosteroids (0.3‐0.4 mg. of betamethasone disodium phosphate daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical oral hydrocortisone hemisuccinate (10 mg. daily for up to three years)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical oral betamethasone 17‐valerate (0.4 mg. per day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Synacthen (tetracosactrin) stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical oral hydrocortisone hemisuccinate and betamethasone 17‐valerate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical oral betamethasone disodium phosphate
Number of subjects: 42
Study: 29105056

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) after induction, 7 cmH2 O positive end‐expiratory pressure (PEEP) during anesthesia and continuous positive airway pressure (CPAP) during emergence with 0.4 inspired oxygen fraction (FiO2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ventilated without LRM, with 0 cmH2 O PEEP, and 1.0 FiO2 during emergence without CPAP application
Number of subjects: 18
Study: 28980935

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (5x10^9 cfu/capsule) for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 80
Study: 25936291

Group type: EXPERIMENTAL
Intervention: Sad film clip
Number of subjects: 182

Group type: COMPARATOR
Intervention: Neutral film clip
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Dietary restraint
Number of subjects: 182
Study: 23982366

Group type: EXPERIMENTAL
Intervention: 400 mg/d of sofosbuvir and weight‐based ribavirin for 24 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mg of sofosbuvir with weight‐based ribavirin for 24 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mg of sofosbuvir with low‐dose 600 mg/d of ribavirin for 24 weeks
Number of subjects: 60
Study: 21502764

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A into both orbicularis oculi and perioral muscles
Number of subjects: 23

Group type: COMPARATOR
Intervention: Botulinum toxin type A into orbicularis oculi and placebo into perioral muscles
Number of subjects: 23
Study: 17392695

Group type: EXPERIMENTAL
Intervention: Isoflavone intake
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Isoflavone intake <90 mg/day
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Isoflavone intake for <12 weeks
Number of subjects: 432
Study: 16815130

Group type: EXPERIMENTAL
Intervention: Five meals per day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Three meals per day
Number of subjects: 31
Study: 12689782

Group type: COMPARATOR
Intervention: High-level spinal cord injury during the lift phase
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-level spinal cord injury muscular demand
Number of subjects: 11

Group type: COMPARATOR
Intervention: Anterior deltoid muscle
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pectoralis major muscle
Number of subjects: 11
Study: 10895746

Group type: EXPERIMENTAL
Intervention: Triamcinolone 40 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Triamcinolone 20 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: No steroid (0 mg)
Number of subjects: 95
Study: 9384397

Group type: EXPERIMENTAL
Intervention: Closed system drainage
Number of subjects: 257

Group type: COMPARATOR
Intervention: Burr-hole irrigation alone
Number of subjects: 257

Group type: COMPARATOR
Intervention: No closed system drainage
Number of subjects: 257

Group type: COMPARATOR
Intervention: High-intensity group
Number of subjects: 257

Group type: COMPARATOR
Intervention: Nonhigh-intensity group
Number of subjects: 257
Study: 8334086

Group type: EXPERIMENTAL
Intervention: Vacuum extractor
Number of subjects: 607

Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 607
Study: 3310826

Group type: EXPERIMENTAL
Intervention: Combination of 0.030 mg ethinylestradiol and 0.150 mg levonorgestrel
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of 0.030 mg ethinylestradiol and 0.150 mg desogestrel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (0.030 mg ethinylestradiol and 0.150 mg levonorgestrel)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (0.030 mg ethinylestradiol and 0.150 mg desogestrel)
Number of subjects: 20
Study: 31948767

Group type: EXPERIMENTAL
Intervention: Ivermectin MDA with three consecutive daily doses of 300 μg/kg (3×300 μg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin MDA added to seasonal malaria chemoprevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin MDA added to MDA with dihydroartemisinin‐piperaquine
Number of subjects: 0
Study: 29338857

Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 1508
Study: 27921413

Group type: EXPERIMENTAL
Intervention: Low-dose phototherapy (mixture of UVA, UVB, and visible light)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Visible light alone (placebo)
Number of subjects: 62
Study: 24693926

Group type: EXPERIMENTAL
Intervention: Standardized treatment at the hospital plus a weekly session with a peer of their choice (Experimental group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard treatment at the hospital plus a weekly interactive and physical activity session (Comparison group)
Number of subjects: 134
Study: 23799702

Group type: EXPERIMENTAL
Intervention: Prescription plus referral intervention (n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prescription only intervention (n = 12)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual care (n = 11)
Number of subjects: 35
Study: 21397440

Group type: EXPERIMENTAL
Intervention: TEVAR with the Talent device
Number of subjects: 195
Study: 18480190

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (physical training twice weekly + cognitive-behavioral training once weekly)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Physical training (twice weekly)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation (physical training + cognitive-behavioral training)
Number of subjects: 209
Study: 16574438

Group type: EXPERIMENTAL
Intervention: NSCLC patients
Number of subjects: 21

Group type: COMPARATOR
Intervention: COPD patients
Number of subjects: 21
Study: 12707193

Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Uvulopalatopharyngoplasty (control)
Number of subjects: 25
Study: 15321086

Group type: EXPERIMENTAL
Intervention: i.v. glycopyrrolate 4.0 microg/kg (group G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 40
Study: 9014624

Group type: EXPERIMENTAL
Intervention: Lignocaine 1% (5 ml) instilled hourly for 12 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.9% saline (5 ml) instilled hourly for 12 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of lignocaine vs saline
Number of subjects: 30
Study: 1359211

Group type: EXPERIMENTAL
Intervention: Nutrient supplementation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 3883172

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (2.5 to 5 mg every 12 hours for three doses weekly)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31550290

Group type: EXPERIMENTAL
Intervention: Verbal suggestion indicating less painful stimuli (green or red colour) in predictable pain condition (PC)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Verbal suggestion indicating less painful stimuli (green or red colour) in unpredictable pain condition (UC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No verbal suggestion (control group) in predictable pain condition (PC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No verbal suggestion (control group) in unpredictable pain condition (UC)
Number of subjects: 56
Study: 30132688

Group type: EXPERIMENTAL
Intervention: Proximal medial gastrocnemius recession and stretching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stretching exercise program only
Number of subjects: 40
Study: 27624603

Group type: EXPERIMENTAL
Intervention: Tolvaptan (Group T)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional loop diuretics (Group C)
Number of subjects: 57
Study: 25373935

Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate (sn-2; n=56)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Formula containing high sn-2 palmitate plus 3 g/L oligofructose (sn-2+OF; n=55)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control formula (n=54)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Human milk-fed group (HM; n=55)
Number of subjects: 165
Study: 22932428

Group type: EXPERIMENTAL
Intervention: i.v. amphetamine dose of 0.3 mg/kg bodyweight
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 19946868

Group type: EXPERIMENTAL
Intervention: Individualized Cognition-Action (CA) intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Routine medical care (C)
Number of subjects: 49
Study: 18444166

Group type: EXPERIMENTAL
Intervention: Topical perillyl alcohol (POH) cream (0.76% wt/wt) applied twice daily for 30 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 30 days
Number of subjects: 25
Study: 16418058

Group type: EXPERIMENTAL
Intervention: Web-based leisure-time physical activity motivational program
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study: 12907905

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (20 U; Botox)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 50
Study: 10504600

Group type: EXPERIMENTAL
Intervention: Computer learning module
Number of subjects: 58

Group type: COMPARATOR
Intervention: Small-group seminar
Number of subjects: 58
Study: 7795830

Group type: EXPERIMENTAL
Intervention: Weight loss alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reduced Na intake alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined weight loss and reduced Na intake
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual life-style (control group)
Number of subjects: 100
Study: 2207867

Group type: EXPERIMENTAL
Intervention: 4% polyacrylamide (Orcolon)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1% sodium hyaluronate (Healon)
Number of subjects: 70
Study: 359140

Group type: EXPERIMENTAL
Intervention: Exercise treatment (low-level physical activity sessions, 14 of 18 sessions over 6 weeks)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 651
Study: 31062722

Group type: EXPERIMENTAL
Intervention: One session of pulsed dye laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Two sessions of pulsed dye laser (2 weeks apart)
Number of subjects: 22
Study: 28341259

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU daily) and isokinetic training (3 times per week at 150°/s)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isokinetic training (3 times per week at 150°/s)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU daily) and isokinetic training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 48
Study: 25629741

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 222
Study: 23494035

Group type: EXPERIMENTAL
Intervention: TT clamp
Number of subjects: 1917

Group type: COMPARATOR
Intervention: Standard bilamellar tarsal rotation (BLTR)
Number of subjects: 1917

Group type: COMPARATOR
Intervention: Standard BLTR
Number of subjects: 1917
Study: 22011820

Group type: EXPERIMENTAL
Intervention: Bovine collagen calcium-alginate dressing covered with transparent polyurethane film (group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transparent polyurethane film dressing (group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rayon soaked in 0.9% saline (group C)
Number of subjects: 34
Study: 19457978

Group type: EXPERIMENTAL
Intervention: Physiotherapy staff recording of treatment time
Number of subjects: 39

Group type: COMPARATOR
Intervention: Video recording of treatment time
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Comparison of both methods
Number of subjects: 39
Study: 16710580

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment 4 times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% ointment 4 times daily
Number of subjects: 40
Study: 15471389

Group type: EXPERIMENTAL
Intervention: Aspirin (250 mg on admission, then 125 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cardiomagnil (150 mg on admission, then 75 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Combination of clopidogrel (75 mg/day) and cardiomagnil (75 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No dysaggregants
Number of subjects: 78
Study: 11204665

Group type: EXPERIMENTAL
Intervention: Oxaliplatin (Eloxatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with novel agents (e.g., thymidylate synthase inhibitors, epidermal growth factor‐receptor antagonists, microtubule interactive agents)
Number of subjects: 0
Study: 9278830

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg intravenously (IV)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: droperidol 25 mcg/kg i.v.
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study: 8318783

Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of DDP at doses of 110 mg/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of DDP at doses of 70 mg/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intraperitoneal injection of DDP with sodium thiosulfate (STS) rescue
Number of subjects: 17
Study: 3519886

Group type: EXPERIMENTAL
Intervention: PC (cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 on day 1 every 28 days)
Number of subjects: 125

Group type: COMPARATOR
Intervention: PAC (PC + doxorubicin 45 mg/m2)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: PC (in 75 patients submitted to second look)
Number of subjects: 125

Group type: COMPARATOR
Intervention: PAC (in 75 patients submitted to second look)
Number of subjects: 125

Group type: COMPARATOR
Intervention: PAC
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: PC
Number of subjects: 125
Study: 29631435

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.7 mg at day 1 and month 5, with optional retreatment at month 10 or 11.
Number of subjects: 307

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg at day 1 and monthly through month 5, with as-needed injections at month 6-11.
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 307

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 307
Study: 27406647

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA) with treated plasma ≥0.20 L/kg/day in the first 3 days after randomisation.
Number of subjects: 190

Group type: COMPARATOR
Intervention: Current clinical practice (control group).
Number of subjects: 190
Study: 25062396

Group type: EXPERIMENTAL
Intervention: Framingham Risk Profile (FRP) scores for patients with SHHD
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Framingham Risk Profile (FRP)
Number of subjects: 149
Study: 22954564

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES) in Japanese patients
Number of subjects: 88

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES) in US patients
Number of subjects: 88
Study: 20111952

Group type: EXPERIMENTAL
Intervention: Arthroscopic anatomic ACL reconstruction with hamstring tendons
Number of subjects: 0
Study: 18799820

Group type: COMPARATOR
Intervention: Enalapril (20 mg/d, n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Perindopril (4 mg/d, n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 90
Study: 15767472

Group type: EXPERIMENTAL
Intervention: Cryotherapy treatment
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control (no cryotherapy)
Number of subjects: 254
Study: 12217141

Group type: EXPERIMENTAL
Intervention: Telehealth interventions
Number of subjects: 6
Study: 10480471

Group type: EXPERIMENTAL
Intervention: 81 mg/day ASA
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 325 mg/day ASA
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8531541

Group type: EXPERIMENTAL
Intervention: Active treatment with Goretex bedcovers, benzyltannate spray, and a high‐filtration vacuum cleaner.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo treatment with cotton covers, water spray, and a conventional domestic vacuum cleaner.
Number of subjects: 48
Study: 1830393

Group type: EXPERIMENTAL
Intervention: Prostaglandin (PG) application
Number of subjects: 23

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sodium chloride treatment
Number of subjects: 23
Study: 6632131

Group type: EXPERIMENTAL
Intervention: Training program for nursing home staff
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 586